Connect your AI

Organon OGN Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

AmgenAMGN

-$959M-9.7%

The Cooper Companies, Inc.COO

$6.98M+675%

BiogenBIIB

-$243.2M+19.1%

Envista Holdings CorporationNVST

-$39.8M-5,075%

PBH

Prestige Consumer HealthcarePBH

$2.44M-35.5%

Merck & Co.MRK

-$460.25M+20.9%

Other financials

Income statement

Revenue$1.5B-3.5%

Gross profit$783.0M-6.9%

Net income$146.0M+67.8%

EPS (diluted)$0.55+66.7%

Balance sheet

Cash & equivalents$1.1B+104%

Total debt$8.6B-4.3%

Total equity$903.0M+66.6%

Total assets$13.0B-1.2%

Cash flow

Operating cash flow$225.0M+200%

CapEx$37.0M+15.6%

Free cash flow$188.0M+337%

Valuation

Market cap$3.53B-59.4%

Profitability

Gross margin52.8%-4.4pp

Net margin8%-12.3pp

FCF margin11.1%-1.3pp

Returns & leverage

Return on equity71.6%—

Debt / equity9.5×-7.0×

Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Organon's change in accrued liabilities?: Organon (OGN) reported change in accrued liabilities of $95M in Q1 2026.
How has Organon's change in accrued liabilities changed year-over-year?: Organon's change in accrued liabilities increased by 143.6% year-over-year, from $39M to $95M.
What is the long-term trend for Organon's change in accrued liabilities?: Over 2 years (2022 to 2025), Organon's change in accrued liabilities has grown at a -9.1% compound annual growth rate (CAGR), from $172M to -$142M.
What does change in accrued liabilities mean?: Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.